Santhamma; Bindu

Patent Applications and Registrations

Patent applications and USPTO patent grants for Santhamma; Bindu.The latest application filed is for "lif/lifr antagonist in oncology and nonmalignant diseases".

Company Profile

4.8.14

Santhamma; Bindu - San Antonio TX

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents Grant 10,738,075 - Nair , et al. A	2020-08-11
Lif/lifr Antagonist In Oncology And Nonmalignant Diseases App 20200087340 - Nair; Hareesh ; et al.	2020-03-19
Novel Cytotoxic Agents That Preferentially Target Leukemia Inhibitory Factor (lif) For The Treatment Of Malignancies And As New App 20190153018 - Nair; Hareesh ; et al.	2019-05-23
Pro-drug forming compounds Grant 10,273,263 - Nickisch , et al.	2019-04-30
Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents Grant 10,053,485 - Nair , et al. August 21, 2	2018-08-21
Progesterone Antagonists App 20180155386 - Nickisch; Klaus ; et al.	2018-06-07
Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer Grant 9,850,273 - Nickisch , et al. December 26, 2	2017-12-26
Pro-drug Forming Compounds App 20170349624 - Nickisch; Klaus ; et al.	2017-12-07
Pro-drug forming compounds Grant 9,745,338 - Nickisch , et al. August 29, 2	2017-08-29
Novel Cytotoxic Agents That Preferentially Target Leukemia Inhibitory Factor (lif) For The Treatment Of Malignancies And As New Contraceptive Agents App 20160279145 - Nair; Hareesh ; et al.	2016-09-29
Combination Of Estrogens Plus Antiprogestins With Significant Partial Agonistic Effect As An Effective Treatment Of Menopausal Symptoms And For Prevention Of The Occurrence Of Breast Cancer App 20160159852 - Nickisch; Klaus ; et al.	2016-06-09
Imidazolyl progesterone antagonists Grant 9,096,641 - Nickisch , et al. August 4, 2	2015-08-04
Pro-drug Forming Compounds App 20150018322 - Nickisch; Klaus ; et al.	2015-01-15
Imidazolyl Progesterone Antagonists App 20140364600 - Nickisch; Klaus ; et al.	2014-12-11
Methods For The Preparation Of Etonogestrel And Desogestrel App 20130123523 - Nickisch; Klaus ; et al.	2013-05-16
Progesterone Antagonists App 20130029953 - Nickisch; Klaus ; et al.	2013-01-31
Methods for the preparation of drospirenone Grant 8,334,375 - Nickisch , et al. December 18, 2	2012-12-18
Methods For The Preparation Of Drospirenone App 20100261896 - Nickisch; Klaus ; et al.	2010-10-14

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.